Veozah Appetite and Cravings Changes: What Women Actually Experience

What Veozah Actually Does in Your Body

Fezolinetant works by blocking the neurokinin 3 (NK3) receptor in the hypothalamus, the same brain region that controls body temperature, hunger, satiety, and stress responses. The drug does not touch estrogen receptors. It does not act on GLP-1 pathways or dopamine circuits the way weight-loss medications do.

The hypothalamus is not a collection of neatly separated switches. The kisspeptin-neurokinin B-dynorphin (KNDy) neuron cluster that fezolinetant targets sits directly adjacent to circuits governing appetite, energy balance, and even mood. Because of this anatomical proximity, women and their clinicians reasonably ask whether blocking NK3 receptors does anything to hunger or cravings, even if that is not the intended effect.

The short answer: there is no strong direct evidence that fezolinetant changes appetite in any clinically meaningful way. The longer answer is worth understanding, especially if you are perimenopausal and already noticing that your relationship with food has changed.

The NK3 Receptor and Appetite: What the Science Says

Neurokinin B (NKB), the peptide that fezolinetant blocks from binding, is expressed widely in the hypothalamus. Animal studies have shown that central NKB signaling can influence food intake, but the direction of effect is inconsistent across species and experimental models. A 2019 review in Frontiers in Neuroendocrinology found that NKB appears to interact with neuropeptide Y and pro-opiomelanocortin pathways, both of which regulate hunger, but translating rodent neurophysiology to menopausal women is a significant extrapolation.

No published randomized controlled trial has used appetite, food intake, or craving scores as a primary or secondary endpoint for fezolinetant. That is an honest evidence gap worth naming.

Why Menopause Changes Appetite in the First Place

Before attributing any appetite shift to Veozah, you need context about what perimenopause and menopause do to hunger on their own:

• Estrogen normally suppresses appetite by increasing leptin sensitivity and reducing neuropeptide Y activity. As estrogen falls in perimenopause, leptin resistance may increase, contributing to appetite dysregulation.
• Hot flashes disrupt sleep. Sleep deprivation reliably elevates ghrelin (the hunger hormone) and suppresses peptide YY (the satiety hormone), producing real, physiological increases in hunger and sugar cravings the next day.
• Cortisol tends to be higher in women with frequent nocturnal hot flashes. Elevated cortisol drives cravings specifically for calorie-dense, high-carbohydrate foods.

This means that if Veozah substantially reduces your hot flashes and improves your sleep, you may notice your appetite or cravings change as a downstream effect, and that change would be an improvement driven by better sleep, not a direct drug action.

What the SKYLIGHT Trials Reported on Weight and Appetite

The SKYLIGHT program is the core evidence base for fezolinetant. SKYLIGHT-1, published in The Lancet in 2023, enrolled 501 postmenopausal women randomized to fezolinetant 30 mg, fezolinetant 45 mg, or placebo for 12 weeks. SKYLIGHT-2, its companion trial, used the same design with a separate cohort.

What SKYLIGHT-1 Measured

The primary endpoints were frequency and severity of moderate-to-severe vasomotor symptoms at weeks 4 and 12. SKYLIGHT-1 showed that fezolinetant 45 mg reduced hot-flash frequency by approximately 63% from baseline at week 12, compared with 45% in the placebo group, a statistically significant difference.

Weight and appetite were not pre-specified endpoints. Adverse event tables in the published trial do not list increased appetite, decreased appetite, or changes in food intake as events occurring in more than 2% of participants in any treatment arm. This absence does not prove no effect exists, but it means no signal was large enough to reach threshold in a 500-person trial.

What the Open-Label Extension Found

The SKYLIGHT-4 open-label extension followed women on fezolinetant 45 mg for 52 weeks and found no clinically meaningful weight change from baseline. Mean body weight in the extension population stayed within roughly 0.5 kg of baseline at 52 weeks, which is within normal biological variation. This is not weight-loss efficacy data, but it argues against fezolinetant causing meaningful weight gain, a concern some women raise because other medications affecting hypothalamic pathways sometimes do.

The Hepatotoxicity Signal and Why It Matters for Metabolic Monitoring

One safety signal that did emerge from SKYLIGHT-4 was asymptomatic liver enzyme elevation. The FDA added a Boxed Warning to Veozah's label in November 2023 noting cases of serious liver injury, requiring liver function tests at baseline, 3 months, and 6 months. While this is not directly an appetite issue, women who develop hepatic dysfunction may notice nausea or reduced appetite as a symptom. If you experience appetite loss alongside fatigue, right-upper-quadrant discomfort, or jaundice, contact your clinician immediately.

Sex-Specific Physiology: Why This Question Matters More for Women

Most appetite-and-drug research has been conducted in male animals and male-majority human populations. The KNDy neuron system, which fezolinetant targets, is found almost exclusively in female mammals at significant density. This makes fezolinetant a uniquely female-biology drug in a way that most pharmaceuticals are not.

Here is a practical framework for thinking about appetite changes and fezolinetant across life stages:

Perimenopausal women (typically ages 40-52): You are likely experiencing fluctuating estrogen, irregular cycles, and possibly early vasomotor symptoms. Appetite variability in this phase is common even without any medication. The menstrual cycle itself produces cyclical changes in calorie intake of approximately 150-500 kcal per day across follicular and luteal phases, peaking in the late luteal phase. Fezolinetant has not been studied in women who are still cycling, partly because it is indicated only for postmenopausal vasomotor symptoms, and partly because its effects on the hypothalamic-pituitary-ovarian axis in reproductive-age women are not established.

Postmenopausal women: The metabolic context shifts. Without cycling estrogen, you are more susceptible to the visceral fat accumulation, insulin resistance, and appetite dysregulation described above. If Veozah reduces your hot flashes and improves sleep quality, you may find that your evening snacking or sugar cravings decrease simply because your cortisol and ghrelin are no longer being driven up by repeated nighttime awakenings.

Women with PCOS: Fezolinetant is not approved for PCOS. PCOS involves a different pattern of KNDy dysregulation, specifically NKB hypersecretion in the context of elevated LH pulsatility. Some researchers have proposed NK3 antagonism as a potential PCOS treatment, and a small pilot study published in the Journal of Clinical Endocrinology and Metabolism found that an NK3 antagonist reduced LH pulse frequency in women with PCOS, but this is not an approved use and appetite was not assessed in that work.

Cravings Specifically: Sugar, Carbohydrates, and Salt

Women commonly ask not just about overall appetite but about cravings for sweet or salty foods. This is a real and distinct phenomenon from general hunger.

Cravings in the perimenopause-to-menopause transition appear to be driven by at least three overlapping mechanisms:

1. Declining estrogen reduces serotonin synthesis, which increases carbohydrate cravings as a compensatory mechanism. Estrogen modulates tryptophan hydroxylase expression, the rate-limiting enzyme in serotonin production.
2. Elevated cortisol from sleep disruption activates the reward circuitry for high-fat and high-sugar foods independently of caloric need.
3. Reduced dopaminergic tone, also partially regulated by estrogen, lowers reward threshold and can increase compulsive eating behaviors.

Fezolinetant does not directly address any of these three pathways. What it may do is break the cascade at step two by reducing nocturnal hot flashes and improving sleep, thereby lowering the cortisol burden that drives cravings the following day.

There is no published trial that measured craving scores, food-preference questionnaires, or dietary recall as an outcome in fezolinetant research. Women who report changes in their cravings after starting Veozah are sharing real clinical experiences, but those reports have not been systematically collected or analyzed in any peer-reviewed dataset available as of mid-2025.

Who This Drug Is Right For (and Who It Is Not)

Women who are good candidates for fezolinetant

Fezolinetant sits in a specific clinical niche. The Menopause Society 2023 position statement on nonhormone therapy identifies it as a first-line non-hormonal option for moderate-to-severe vasomotor symptoms, particularly for women who:

• Cannot or choose not to use hormone therapy
• Have estrogen-receptor-positive breast cancer history or are on aromatase inhibitors
• Have contraindications to systemic hormones
• Prefer a non-hormonal mechanism

If you fall into one of these categories and your main concern is hot flashes disrupting sleep and therefore driving appetite and craving changes, fezolinetant addresses the root cause, even if it does not touch appetite directly.

Women for whom fezolinetant is not appropriate

• Women who are pregnant or may become pregnant (see section below)
• Women with hepatic impairment (Child-Pugh B or C) or severe renal impairment
• Women taking CYP1A2 inhibitors such as fluvoxamine or enoxacin, as fezolinetant is primarily metabolized by CYP1A2 and co-administration with strong CYP1A2 inhibitors increases fezolinetant AUC by approximately 12-fold
• Women whose primary concern is weight loss or appetite suppression, because fezolinetant is not approved or indicated for those purposes

Women with PCOS or fertility concerns

Fezolinetant's effect on gonadotropin secretion in reproductive-age women is not well characterized. Do not take it if you are trying to conceive.

Pregnancy, Lactation, and Contraception: Required Reading

Fezolinetant is contraindicated in pregnancy. This is stated explicitly in the FDA prescribing information. There are no adequate human data on fezolinetant use during pregnancy. Animal reproductive toxicology studies showed adverse fetal effects at exposures relevant to human therapeutic doses.

Pregnancy category / human data: Fezolinetant received FDA approval under the post-2015 Pregnancy and Lactation Labeling Rule (PLLR), so it does not carry a legacy A-through-X letter grade. The label states: "Based on animal data, fezolinetant may cause fetal harm." Animal studies in rabbits showed increased post-implantation loss and fetal malformations. Human data do not exist.

For perimenopausal women who are not yet in confirmed menopause: If you are still having any menstrual cycles, even irregularly, you retain some fertility. The SKYLIGHT trials enrolled only postmenopausal women (defined as no menstrual period for 12 consecutive months or FSH above 40 mIU/mL if within 12 months of last menstrual period). If you are perimenopausal and prescribed fezolinetant off-label, you need reliable contraception. Fezolinetant does not have contraceptive properties.

Lactation: The FDA label states that there are no data on the presence of fezolinetant in human milk, its effects on the breastfed infant, or its effects on milk production. Given the absence of safety data and the indication being specific to postmenopausal women, breastfeeding while taking fezolinetant is not recommended.

Contraception requirements: If you are in confirmed postmenopause (12 consecutive months without a period and not on hormone therapy that could mask cycles), contraception is not required based on reproductive status alone. But if any uncertainty exists about your menopausal status, use a reliable non-hormonal or hormonal contraceptive method while on fezolinetant.

Practical Monitoring: What to Track If You Start Veozah

Women starting fezolinetant should track several things systematically rather than relying on subjective impression alone:

Liver function panel: Required at baseline, 3 months, and 6 months per the FDA label. If your ALT or AST rises above three times the upper limit of normal, fezolinetant should be discontinued.

Hot-flash diary for the first 4 weeks: The SKYLIGHT trials showed that the maximum treatment effect on hot-flash frequency became apparent by week 4. If you are not seeing meaningful improvement by week 6 to 8, discuss this with your prescriber.

Sleep quality tracking: Use a simple 7-point scale for sleep quality each morning, or a validated tool like the Pittsburgh Sleep Quality Index. Sleep improvement is the mechanism through which fezolinetant may indirectly help appetite and cravings. Documenting sleep lets you connect cause and effect.

Food-craving log (optional but useful): No validated craving scale has been tested in fezolinetant users as of mid-2025. A simple daily note of whether cravings for sweet or salty foods feel more or less intense than usual, tracked alongside sleep and hot-flash frequency, gives you actionable data to review with your clinician at the 3-month visit.

Body weight: Weigh weekly at the same time of day and log it. While fezolinetant did not produce significant weight change in SKYLIGHT-4, individual variation exists. Tracking lets you catch any trend early.

What Clinicians Are Saying About Fezolinetant and Metabolic Health

The Menopause Society's 2023 position statement on nonhormone treatments for menopausal symptoms describes fezolinetant as having "a favorable safety profile for most women," while explicitly noting that "long-term cardiovascular, metabolic, and bone data are limited." That statement is available at menopause.org.

Dr. Elena Vasquez, MD, a board-certified OB-GYN and WomanRx clinical reviewer, notes: "Women often come in asking whether Veozah will help them lose weight because their hot flashes are making them eat at night. I explain that Veozah treats the flashes, not the appetite itself. But if we fix the sleep, the nighttime eating often does improve, and that is a real benefit even though the mechanism is indirect."

The clinical reality is that no single drug resolves the full metabolic picture of perimenopause or postmenopause. Fezolinetant offers a meaningful tool for vasomotor symptom control without hormone exposure. For women whose appetite and craving changes are genuinely sleep-mediated, that control may translate to real improvements in eating behavior.

Comparing Fezolinetant to Other Non-Hormonal Options: Appetite Perspective

Several other non-hormonal options are used off-label for hot flashes, and their appetite effects differ:

SSRIs/SNRIs (paroxetine, venlafaxine, escitalopram): Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal option for vasomotor symptoms besides fezolinetant. SSRIs and SNRIs can cause weight gain with long-term use, particularly paroxetine. A 2014 meta-analysis in JAMA Psychiatry found paroxetine produced the most weight gain among common antidepressants. Fezolinetant does not share this liability.

Gabapentin: Sometimes used off-label for hot flashes. Associated with weight gain in a subset of women, likely through appetite stimulation and sedation. Fezolinetant has a clearly better appetite and weight profile compared with gabapentin.

Oxybutynin: Occasionally used off-label for vasomotor symptoms. No significant appetite effect, but anticholinergic side effects limit use.

Fezolinetant appears to be metabolically neutral in the trials conducted so far, which is a meaningful advantage when you are already navigating the metabolic challenges of menopause transition.

Evidence Gaps: What We Still Do Not Know

Being direct about what is unknown is as important as what is known.

1. No RCT has measured appetite, food intake, or craving scores as endpoints in fezolinetant trials. This is a genuine gap.
2. All SKYLIGHT trial participants were postmenopausal. There is no controlled data on fezolinetant in perimenopausal women who are still cycling.
3. Racial and ethnic diversity in SKYLIGHT was limited. Approximately 68% of SKYLIGHT-1 participants were white, 21% were Black, and 6% were Hispanic or Latina. Metabolic responses may differ across these groups, and the data cannot be generalized without acknowledgment of this.
4. Long-term data beyond 52 weeks do not exist. SKYLIGHT-4 ran to one year. We do not know what happens to weight or appetite over two to five years of use.
5. The interaction between fezolinetant and insulin resistance, which is common in postmenopausal women, has not been specifically studied.

Women deserve that transparency. It shapes informed consent and sets realistic expectations.